Health Hub
Sourced from the NHS, the MHRA, Cochrane, the New England Journal of Medicine, the BMJ and The Lancet.
117 articles
Orforglipron was authorised for blood sugar control as well as weight management. What that means, how it fits alongside existing diabetes treatment, and why the distinction matters.
Curate Editorial5 min read
A trial switched people who had finished 72 weeks on an injectable onto a daily tablet. Those who switched held their weight; the placebo group regained. What that does and does not show.
Curate Editorial5 min read
Around 11% average weight loss over 72 weeks, and a good deal more detail behind that figure. What ATTAIN-1 and ATTAIN-2 actually measured, and what an average does not tell you.
Curate Editorial5 min read
A daily tablet against a weekly injection, with a real difference in trial results. How the two compare on effectiveness, practicality and side effects.
Curate Editorial5 min read
Both are daily weight-loss tablets, but they work through completely different chemistry. One is easier to take, the other produced more weight loss in trials.
Curate Editorial5 min read
Both are made by Eli Lilly, but one is a daily tablet and the other a weekly injection that produced roughly twice the average weight loss. An honest comparison.
Curate Editorial5 min read
No, and that matters. Why nothing sold as orforglipron in the UK today can be legitimate, what the risks are, and how to check whether a pharmacy is genuine.
Curate Editorial5 min read
NICE is appraising orforglipron with guidance due on 18 November 2026. How the NHS funding decision works, what it will weigh, and what a yes would realistically mean.
Curate Editorial5 min read
The UK became the first country in Europe to authorise orforglipron on 10 August 2026. What the MHRA assessed, what the decision covers, and what it does not.
Curate Editorial5 min read
Authorised on 10 August 2026, but not yet on sale. What still has to happen before orforglipron can be prescribed, and why approval and availability are not the same thing.
Curate Editorial5 min read
The authorised criteria are a BMI of 30 or above, or 27 to 30 with a weight-related condition. What that means in practice, and why meeting them is not the same as being suitable.
Curate Editorial5 min read
One tablet daily, any time, with or without food or water. Why orforglipron has none of the restrictions the Wegovy pill requires, and the few rules that do apply.
Curate Editorial5 min read
